{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:32:53Z","timestamp":1784302373562,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>As a newly approved immune checkpoint inhibitor in China, serplulimab has been widely used in the immunotherapy of tumors. However, the immune-related adverse events of immune checkpoint inhibitors should not be ignored. Although immune checkpoint inhibitor-induced type 1 diabetes mellitus is a rare complication, it may cause diabetic ketoacidosis and endanger the lives of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>This case report describes a 55-year-old male of Han nationality from China diagnosed with small-cell lung cancer with multiple metastases who experienced an adverse event of type 1 diabetes mellitus 68\u00a0weeks after receiving serplulimab therapy. The patient presented with typical symptoms of diabetic ketoacidosis, including severe thirst, nausea, vomiting, deep respirations, and stupor. Despite the absence of diabetes-related autoantibodies, the patient had extremely low levels of insulin and C-peptide release. Other potential causes of diabetes were ruled out, confirming the condition as serplulimab-induced immune checkpoint inhibitor-induced type 1 diabetes mellitus. After aggressive treatment to correct diabetic ketoacidosis, the patient\u2019s blood glucose levels stabilized and symptoms of diabetes improved significantly, although long-term insulin maintenance therapy was necessary.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This case highlights a rare, late-onset adverse event of immune checkpoint inhibitor-induced type 1 diabetes mellitus that may be overlooked during treatment with serplulimab. The monitoring of blood glucose levels and early signs and symptoms of diabetes cannot be relaxed at the late stage of treatment, even if patients do not have elevated blood glucose levels before and during the middle stage of treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-04248-7","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T01:02:12Z","timestamp":1705885332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the\u00a0literature"],"prefix":"10.1186","volume":"18","author":[{"given":"Peng","family":"Ning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"issue":"8","key":"4248_CR1","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.7150\/ijbs.82776","volume":"19","author":"H Hu","year":"2023","unstructured":"Hu H, Wang K, Jia R, Zeng ZX, Zhu M, Deng YL, et\u00a0al. Current status in rechallenge of immunotherapy. Int J Biol Sci. 2023;19(8):2428\u201342.","journal-title":"Int J Biol Sci"},{"key":"4248_CR2","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","volume":"14","author":"Q Yin","year":"2023","unstructured":"Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, et\u00a0al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975.","journal-title":"Front Immunol"},{"issue":"1","key":"4248_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41698-023-00380-1","volume":"7","author":"RJ Verheijden","year":"2023","unstructured":"Verheijden RJ, van Eijs MJM, May AM, van Wijk F, Suijkerbuijk KPM. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. NPJ Precis Oncol. 2023;7(1):41.","journal-title":"NPJ Precis Oncol"},{"issue":"15","key":"4248_CR4","doi-asserted-by":"publisher","first-page":"5161","DOI":"10.3390\/jcm12155161","volume":"12","author":"NI Profili","year":"2023","unstructured":"Profili NI, Castelli R, Gidaro A, Merella A, Manetti R, Palmieri G, et\u00a0al. Endocrine Sij de effects in patients treated with immune checkpoint inhibitors: a narrative review. J Clin Med. 2023;12(15):5161.","journal-title":"J Clin Med"},{"issue":"5","key":"4248_CR5","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2337\/dc21-2213","volume":"45","author":"X Chen","year":"2022","unstructured":"Chen X, Affinati AH, Lee Y, Turcu AF, Henry NL, Schiopu E, et\u00a0al. Immune checkpoint inhibitors and risk of type 1 diabetes. Diabetes Care. 2022;45(5):1170\u20136.","journal-title":"Diabetes Care"},{"issue":"1","key":"4248_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/0897190019850929","volume":"34","author":"KA Farina","year":"2021","unstructured":"Farina KA, Kane MP. Programmed cell death-1 monoclonal antibody therapy and type 1 diabetes mellitus: a review of the literature. J Pharm Pract. 2021;34(1):133\u201340.","journal-title":"J Pharm Pract"},{"issue":"10","key":"4248_CR7","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s40265-022-01740-0","volume":"82","author":"A Lee","year":"2022","unstructured":"Lee A. Serplulimab: first approval. Drugs. 2022;82(10):1137\u201341.","journal-title":"Drugs"},{"issue":"12","key":"4248_CR8","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/s41416-022-02001-3","volume":"127","author":"S Qin","year":"2022","unstructured":"Qin S, Li J, Zhong H, Jin C, Chen L, Yuan X, et\u00a0al. Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial. Br J Cancer. 2022;127(12):2241\u20138.","journal-title":"Br J Cancer"},{"issue":"12","key":"4248_CR9","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et\u00a0al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 2022;328(12):1223\u201332.","journal-title":"JAMA"},{"issue":"8","key":"4248_CR10","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","volume":"22","author":"EC Scott","year":"2023","unstructured":"Scott EC, Baines AC, Gong Y, Moore R Jr, Pamuk GE, Saber H, et\u00a0al. Trends in the approval of cancer therapies by the FDA in the twenty-first century. Nat Rev Drug Discov. 2023;22(8):625\u201340.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4248_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3892\/ijo.2023.5534","volume":"63","author":"Y Wang","year":"2023","unstructured":"Wang Y, Yang S, Wan L, Ling W, Chen H, Wang J. New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review). Int J Oncol. 2023;63(1):86.","journal-title":"Int J Oncol"},{"issue":"4","key":"4248_CR12","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4248_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et\u00a0al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20(1):44.","journal-title":"Cell Commun Signal"},{"issue":"7","key":"4248_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021;17(7):389\u201399.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"4248_CR15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11154-020-09618-w","volume":"22","author":"V Lo Preiato","year":"2021","unstructured":"Lo Preiato V, Salvagni S, Ricci C, Ardizzoni A, Pagotto U, Pelusi C. Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature. Rev Endocr Metab Disord. 2021;22(2):337\u201349.","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"4248_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1530\/EJE-19-0291","volume":"181","author":"JMK de Filette","year":"2019","unstructured":"de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, et\u00a0al. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol. 2019;181(3):363\u201374.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"4248_CR17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41574-020-00443-4","volume":"17","author":"BO Roep","year":"2021","unstructured":"Roep BO, Thomaidou S, van Tienhoven R, Zaldumbide A. Type 1 diabetes mellitus as a disease of the \u03b2-cell (do not blame the immune system?). Nat Rev Endocrinol. 2021;17(3):150\u201361.","journal-title":"Nat Rev Endocrinol"},{"issue":"49","key":"4248_CR18","doi-asserted-by":"publisher","first-page":"31319","DOI":"10.1073\/pnas.2019743117","volume":"117","author":"H Hu","year":"2020","unstructured":"Hu H, Zakharov PN, Peterson OJ, Unanue ER. Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice. Proc Natl Acad Sci U S A. 2020;117(49):31319\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"4248_CR19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.156330","volume":"7","author":"AL Perdigoto","year":"2022","unstructured":"Perdigoto AL, Deng S, Du KC, Kuchroo M, Burkhardt DB, Tong A, et\u00a0al. Immune cells and their inflammatory mediators modify \u03b2 cells and cause checkpoint inhibitor-induced diabetes. JCI Insight. 2022;7(17): e156330.","journal-title":"JCI Insight"},{"issue":"2","key":"4248_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/cei.13424","volume":"200","author":"Z Quandt","year":"2020","unstructured":"Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol. 2020;200(2):131\u201340.","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"4248_CR21","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2337\/dbi18-0002","volume":"67","author":"AM Stamatouli","year":"2018","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et\u00a0al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471\u201380.","journal-title":"Diabetes"},{"issue":"12","key":"4248_CR22","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.2337\/dc20-0609","volume":"43","author":"DJ Byun","year":"2020","unstructured":"Byun DJ, Braunstein R, Flynn J, Zheng J, Lefkowitz RA, Kanbour S, et\u00a0al. Immune checkpoint inhibitor-associated diabetes: a single-institution experience. Diabetes Care. 2020;43(12):3106\u20139.","journal-title":"Diabetes Care"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04248-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-04248-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-04248-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T01:02:15Z","timestamp":1705885335000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-04248-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4248"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-04248-7","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"assertion":[{"value":"19 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research is conducted in a responsible and ethically accountable way, with no harm to humans. This research may lead to beneficial outcomes in future similar cases.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}